Prediction of ARrhythmic Events With Positron Emission Tomography II

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

302 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-08

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sudden cardiac death continues to be a major contributor to mortality in patients with ischemic cardiomyopathy. While implantable defibrillators can prevent death from ventricular arrhythmias, our current approach to identify patients at highest risk primarily rests on demonstrating a reduction in left ventricular ejection fraction less than 35%. The purpose of this observational cohort study is to prospectively test whether this can be enhanced by quantifying the amount of sympathetic denervation, left ventricular end-diastolic volume or brain natriuretic peptide levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Noninvasive Electrocardiographic Imaging for Individuals at Risk for Apparently Idiopathic Ventricular Fibrillation.

NCT03963271

Ventricular Fibrillation Ventricular Arrythmia Polymorphic Ventricular Tachycardia +7 more

UNKNOWN

Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy

NCT06730464

Dilated Cardiomyopathy Arrhythmogenic Cardiomyopathy Ventricular Arrhythmia +1 more

RECRUITING

Left Ventricular Septal Pacing: Potential Application for Cardiac Resynchronization Therapy

NCT03415945

Heart Failure Cardiac Resynchronization Therapy Left Bundle-Branch Block

UNKNOWN NA

Routine Mini-invasive Electrophysiology Study for Patients Feeling Tachycardia, With a Negative Holter ECG

NCT00251121

Pre-excitation Syndromes Paroxysmal Tachycardia Atrial Fibrillation +2 more

COMPLETED NA

Mobile Cardiac Outpatient Telemetry for Unexplained Syncope

NCT05957315

Syncope Arrhythmia Near Syncope +1 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Using current guidelines based primarily on ejection fraction (EF), only one-quarter of patients receiving an implantable cardiac defibrillator (ICD) for the primary prevention of sudden cardiac arrest (SCA) require appropriate ICD therapy within 5 years. The NIH-sponsored PAREPET study (Prediction of ARrhythmic Events with Positron Emission Tomography, ClinicalTrials.gov, NCT01400334) identified four independent risk factors that predict SCA or ICD equivalent in patients with ischemic cardiomyopathy. Using retrospectively defined cut-points, the absence of these risk factors identified 38% of the cohort with a very low risk of SCA (\<1% per year). This rate is actually lower than the 1.5-2% annual rate of SCA among patients with coronary artery disease and mild left ventricular (LV) dysfunction, who are not considered candidates for a primary prevention ICD. This proposal will prospectively determine whether these risk factors can form the basis of a clinically applicable approach to identify a subgroup of patients who are candidates for an ICD, but are at low enough risk of SCA to have an ICD safely withheld. Our long-term goal is to develop better approaches to identify patients with coronary artery disease who are most likely to benefit from prevention of SCA with placement of an implantable defibrillator.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sudden Cardiac Arrest Ischemic Cardiomyopathy Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET scan quantifying sympathetic denervation using [18F]-LMI1195

A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer \[18F\]-LMI1195

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Coronary artery disease (by cardiac catheterization or definite myocardial infarction)
* ICD implantation for the primary prevention of SCA
* Primary prevention patients with a Biventricular ICD

* Eligible immediately when this is placed to prevent dysynchrony related to intermittent RV pacing and the native QRS duration is ≤ 130 msec in the absence of pacing.
* Eligible 6 months after implantation when the native QRS duration prior to implant is \>130 msec or there is persistent RV pacing.
* Optimal medical therapy for heart failure.

Exclusion Criteria

* Plans for coronary revascularization (due to the independent impact on SCA)
* Contraindication for PET (i.e. claustrophobia, pregnancy, physical limitation)
* Tricyclic antidepressant use (inhibits norepinephrine and LMI1195 uptake)
* Comorbidities limiting life expectancy \<2yr.
* Age \<18 years or inability to provide informed consent
* Primary prevention ICD/BiV recipients who have received an appropriate ICD shock prior to enrollment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No